Background: Hypercoagulability and a tendency for thromboembolic complications are reported in Cushing’s syndrome (CS). The hypercoagulability is due mainly to the cortisol-induced increase in von Willebrand factor (VWF) and factor VIII. This is not a constant feature of CS, however; it depends on particular single nucleotide polymorphism (SNP) haplotypes in the VWF gene promoter: haplotype 1 (–3268G/–2709C/–2661A/–2527G) confers a greater risk of VWF upregulation by cortisol than haplotype 2 (–3268C/ –2709T/–2661G/–2527A). In healthy individuals these SNPs are in linkage disequilibrium with the –2144 (GT)n of the VWF promoter: haplotype 1 mainly segregates with short GT repeats (15–19, GTs), haplotype 2 with long repeats (GT ≧ 20, GTL). Methods: We analyzed the (GT)n locus, the SNP haplotypes and their association with VWF levels in 80 CS patients in order to precisely define the cortisol-sensitive VWF promoter pattern. CS patients were divided into groups A (increased VWF) and B (normal VWF). Results: Haplotype 1 and (GT)S were more frequent in group A patients, and conferred a 9- and 7.5-fold risk of developing high VWF levels, respectively. Haplotype 2 and (GT)L were more represented in group B. There was also an unexpected higher prevalence of recombinant SNP haplotypes in CS patients (6.2%) than in normals (0.9%), p = 0.002. Conclusions: Our results indicate that the cortisol-induced increase in VWF may be predicted by VWF promoter polymorphisms, haplotype 1 and (GT)S being the sensitive pattern. These represent new markers for defining the prothrombotic risk of CS. The clinical significance, if any, of the increased recombination rate in SNP haplotypes in the VWF promoter warrants further study.

Journal Section:
Editor's choice
Keywords:
Cushing’s syndrome, Von Willebrand factor, Hypercoagulable state of Cushing’s syndrome, Von Willebrand factor promoter single nucleotide polymorphisms, Von Willebrand factor promoter (GT)<sub>n</sub>
1.
Boscaro M, Barzon L, Fallo F, Sonino N: Cushing’s syndrome. Lancet 2001;357:783–791.
[PubMed]
https://doi.org/10.1016%2FS0140-6736%2800%2904172-6
2.
Etxabe J, Vazquez JA: Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol1994;40:479–484.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2265.1994.tb02486.x
3.
Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller HR, Brandjes DP: Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab2009;94:2743–2750.
[PubMed]
https://doi.org/10.1210%2Fjc.2009-0290
4.
Dal Bo Zanon R, Fornasiero L, Boscaro M, Ruffato G, Luzzato G, Fabris F, Girolami A: Clotting changes in Cushing’s syndrome: elevated factor VIII activity. Folia Haematol 1983;110:268–277.
5.
Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A: Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 1985;54:518–520.
[PubMed]
6.
Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM: Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 2000;23:145–150.
[PubMed]
7.
Ruggeri ZM: Von Willebrand factor. Curr Opin Hematol 2003;10:142–149.
[PubMed]
https://doi.org/10.1097%2F00062752-200303000-00008
8.
Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR: The effect of ABO blood group in the diagnosis of von Willebrand disease. Blood 1987;69:1691–1695.
[PubMed]
9.
Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A, Scaroni C: Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 2008;140:230–235.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2141.2007.06907.x
10.
Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D: Variation at the von Willebrand factor (VWF) gene locus is associated with plasma VWF levels: identification of three novel single nucleotide polymorphisms in the VWF gene promoter. Blood 1999;93:4277–4283.
[PubMed]
11.
Harvey PJ, Keightley AM, Lam YM, Cameron C, Lillicrap D: A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. Br J Haematol 2000;109:349–353.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2141.2000.02000.x
12.
Daidone V, Cattini MG, Pontara E, Sartorello F, Gallinaro L, Marotti A, Scaroni C, Pagnan A, Casonato A: Microsatellite (GT)n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. Thromb Haemost 2009;101:298–304.
[PubMed]
13.
Hough C, Cameron CL, Notley CR, Brown C, O’Brien L, Keightley AM, Berber E, Lillicrap D: Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter. J Thromb Haemost 2008;6:1183–1190.
[PubMed]
https://doi.org/10.1111%2Fj.1538-7836.2008.03011.x
14.
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–5602.
[PubMed]
https://doi.org/10.1210%2Fjc.2003-030871
15.
Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A: Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002;99:180–184.
[PubMed]
https://doi.org/10.1182%2Fblood.V99.1.180
16.
Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A: Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinolysis 1999;10:145–151.
[PubMed]
https://doi.org/10.1097%2F00001721-199904000-00006
17.
Ou XM, Chen K, Shih JC: Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 2006;281:21512–21525.
[PubMed]
https://doi.org/10.1074%2Fjbc.M600250200
18.
Hayashi R, Wada H, Ito K, Adcock IM: Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500:51–62.
[PubMed]
https://doi.org/10.1016%2Fj.ejphar.2004.07.011
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.